BPC-157 + TB-500 blend calculator

This vial

5 mg BPC-157 + 5 mg TB-500 (10 mg total)

Water

Dose of

BPC-157 amount

mcg

1 mg = 1000 mcg.

Your syringe

Draw this much

0.0units

0.200 mL · 2,500 mcg/mL

0 units0.3 mL barrel, U-100 scale30 units

Draw: 0.200 mL
Total per draw: 1,000 mcg
Doses per vial: 10

Reference only · Not medical advice

This draw also delivers 500 mcg TB-500.

BPC-157 concentration2,500 mcg/mL

TB-500 concentration2,500 mcg/mL

Blends come as one vial with a fixed mix, so every draw carries both compounds in this ratio. Running two separate vials? That is a stack: see the BPC-157 + TB-500 stack page.

BPC-157 draw

Vial5 mg BPC-157 + 5 mg TB-500 (10 mg total)

BPC-157 in this vial5 mg

Water2 mL

Concentration2,500 mcg/mL

Dose500 mcg

Draw20 units

Syringe0.3 mL, U-100

Also delivers TB-500500 mcg

www.undergroundbiohacking.com · For tracking and calculation purposes only. Not medical advice.

For tracking and calculation purposes only. Not medical advice. Based on a standard U-100 insulin syringe.

How the units are worked out

Your vial holds a fixed amount of peptide. The water you add sets the concentration (how much peptide sits in each millilitre). The concentration then decides how much liquid carries your dose.

Three steps, in order:

Concentration (mcg/mL) = peptide in the vial (mcg) divided by water added (mL).
Volume (mL) = your dose (mcg) divided by the concentration (mcg/mL).
Units to draw = volume (mL) multiplied by 100.

That last step is the syringe, not the peptide. A U-100 insulin syringe is marked so 100 units hold 1 mL, so 0.1 mL reads as 10 units.

A worked example

These are the numbers in the calculator above, worked through: 5 mg BPC-157 of the 10 mg vial + 2 mL = 2,500 mcg/mL. 500 mcg = 0.20 mL = 20 units on a 0.3 mL syringe, which also delivers 500 mcg TB-500.

Change any number in the tool and this line changes with it. The link in your address bar carries the numbers, so you can save it or send it to yourself.

Water and units at a glance

The vial sizes BPC-157 + TB-500: The Injury Recovery Stack is sold in, at different water volumes, with BPC-157 as the amount you name. Every row opens the calculator on that mix.

Vial total	Water	BPC-157 units	Same draw delivers
10 mg	1 mL	10 units	500 mcg TB-500
10 mg	2 mL	20 units	500 mcg TB-500
10 mg	3 mL	30 units	500 mcg TB-500
10 mg	5 mL	50 units	500 mcg TB-500
20 mg	1 mL	5 units	500 mcg TB-500
20 mg	2 mL	10 units	500 mcg TB-500
20 mg	3 mL	15 units	500 mcg TB-500
20 mg	5 mL	25 units	500 mcg TB-500

You never choose the TB-500 column. The vial is one fixed mix, so it comes out of the same draw.

Composition as sold by vendors in our register; most-used water and draw from WPA dosing data, Aug 2026. Not a recommendation.

Mixing and storage

Run the water down the inside wall of the vial and let the powder dissolve on its own. Never shake it. Label the vial with the compound, the total mass, the water you added, the concentration and the date. A sealed freeze-dried vial keeps 12 to 24 months in the fridge at 2 to 8°C. Once mixed with preserved water, such as bacteriostatic water, that drops to roughly 28 days refrigerated. Keep it at the back of the fridge, away from light and away from the door's temperature swings.

Other compounds

Questions

Can I run BPC-157 and TB-500 at lower doses if I'm sensitive to injections or new to peptides?

Yes. Starting BPC-157 at 250 mcg daily and TB-500 at 1 mg twice weekly during the loading phase is a reasonable conservative approach. The dose-response relationship in human tissue is not well characterised, so lower doses may still produce meaningful effects. Increase only if you are tolerating the lower range well after two weeks.

How long before I should expect to see functional improvement in a partial tendon tear?

Preclinical data shows measurable collagen organisation at 4 weeks, but functional return-to-load typically requires 8-12 weeks in moderate soft-tissue injuries. The stack accelerates biological repair; it does not bypass the remodelling process. Injuries involving more than 50% cross-sectional area damage may require surgical assessment regardless of peptide use.

What if I see no improvement after 8 weeks?

Reassess the diagnosis first. Non-response is often a signal that the injury is more complex than initially thought, that the rehabilitation loading programme is inadequate, or that the compound quality is poor. Do not increase dose unilaterally as a first response. A clinical review of imaging and rehab protocol is the appropriate next step.

Can I stack this with other peptides like GHK-Cu or collagen-stimulating compounds?

No formal interaction data exists for these combinations, but GHK-Cu is commonly used alongside BPC-157 and TB-500 in the recovery space without widely reported adverse effects. The practical concern is managing multiple injection schedules accurately and maintaining peptide quality across a more complex protocol. Adding compounds also makes it harder to identify which is producing benefit or causing side effects.

Is there a cancer risk I should be aware of before starting?

Both BPC-157 and TB-500 are pro-angiogenic, meaning they promote blood vessel formation. The theoretical concern is that pre-existing undiagnosed neoplastic tissue could receive enhanced blood supply. This is a preclinical mechanistic concern, not a confirmed clinical finding in humans, but it is not dismissible. Anyone with a personal or family history of cancer should discuss this specifically with a clinician before use.

Does injection site location matter for TB-500 the way it does for BPC-157?

Less so. TB-500 distributes systemically after subcutaneous injection, so proximity to the injury is not the primary driver of its effect. BPC-157, by contrast, shows more pronounced local action when injected near the target tissue. For TB-500, a convenient subcutaneous site such as the abdomen is standard practice.